Prediction of response to combination chemotherapy with irinotecan in Greek patients with metastatic colorectal cancer | Zendy

Maria Gazouli | Zendy; Athina Isaakidou | Zendy; Gerasimos Aravantinos | Zendy; Dimitrios Pectasides | Zendy; George Theodoropoulos | Zendy

AI Assistant Blog Pricing

Open Access

Prediction of response to combination chemotherapy with irinotecan in Greek patients with metastatic colorectal cancer

Author(s) -

Maria Gazouli,

Athina Isaakidou,

Gerasimos Aravantinos,

Dimitrios Pectasides,

George Theodoropoulos

Publication year - 2016

Publication title -

journal of cancer research and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.475

H-Index - 39

eISSN - 1998-4138

pISSN - 0973-1482

DOI - 10.4103/0973-1482.148654

Subject(s) - irinotecan , medicine , kras , colorectal cancer , panitumumab , oncology , capecitabine , cancer

The aim of our study was to analyze the possible relationships between treatment efficacy, and germinal gene polymorphisms linked to the irinotecan in combination with bevasizumab or panitumumab and capecitabine or 5-FU that has been routinely used in our practice, in the management of metastatic colorectal cancer (CRC).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog